ID   TPSN_HUMAN              Reviewed;         448 AA.
AC   O15533; A2AB91; A2ABC0; B0V003; B0V0A6; B2ZUA4; E9PGM2; O15210; O15272;
AC   Q5STJ8; Q5STK6; Q5STQ5; Q5STQ6; Q66K65; Q96KK7; Q9HAN8; Q9UEE0; Q9UEE4;
AC   Q9UIZ6; Q9Y6K2;
DT   24-JAN-2001, integrated into UniProtKB/Swiss-Prot.
DT   23-FEB-2022, sequence version 2.
DT   28-JAN-2026, entry version 221.
DE   RecName: Full=Tapasin {ECO:0000303|PubMed:12582157};
DE            Short=TPN;
DE            Short=TPSN;
DE   AltName: Full=NGS-17;
DE   AltName: Full=TAP-associated protein;
DE   AltName: Full=TAP-binding protein;
DE   Flags: Precursor;
GN   Name=TAPBP {ECO:0000312|HGNC:HGNC:11566}; Synonyms=NGS17, TAPA;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), PARTIAL PROTEIN SEQUENCE, AND
RP   VARIANT ARG-260.
RC   TISSUE=Lymphoblast;
RX   PubMed=9238042; DOI=10.1073/pnas.94.16.8708;
RA   Li S., Sjoegren H.-O., Hellman U., Pettersson R.F., Wang P.;
RT   "Cloning and functional characterization of a subunit of the transporter
RT   associated with antigen processing.";
RL   Proc. Natl. Acad. Sci. U.S.A. 94:8708-8713(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT ARG-260.
RC   TISSUE=B-cell;
RX   PubMed=9271576; DOI=10.1126/science.277.5330.1306;
RA   Ortmann B., Copeman J., Lehner P.J., Sadasivan B., Herberg J.A.,
RA   Grandea A.G., Riddell S.R., Tampe R., Spies T., Trowsdale J., Cresswell P.;
RT   "A critical role for tapasin in the assembly and function of multimeric MHC
RT   class I-TAP complexes.";
RL   Science 277:1306-1309(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT ARG-260.
RX   PubMed=9521053;
RX   DOI=10.1002/(sici)1521-4141(199802)28:02<459::aid-immu459>3.0.co;2-z;
RA   Herberg J.A., Sgouros J., Jones T., Copeman J., Humphray S.J., Sheer D.,
RA   Cresswell P., Beck S., Trowsdale J.;
RT   "Genomic analysis of the Tapasin gene, located close to the TAP loci in the
RT   MHC.";
RL   Eur. J. Immunol. 28:459-467(1998).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=9545376; DOI=10.1006/jmbi.1998.1637;
RA   Herberg J.A., Beck S., Trowsdale J.;
RT   "TAPASIN, DAXX, RGL2, HKE2 and four new genes (BING 1, 3 to 5) form a dense
RT   cluster at the centromeric end of the MHC.";
RL   J. Mol. Biol. 277:839-857(1998).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1), POLYMORPHISM, AND
RP   VARIANT ARG-260.
RC   TISSUE=Lymphocyte;
RX   PubMed=9802609; DOI=10.1111/j.1399-0039.1998.tb03044.x;
RA   Furukawa H., Kashiwase K., Yabe T., Ishikawa Y., Akaza T., Tadokoro K.,
RA   Tohma S., Inoue T., Tokunaga K., Yamamoto K., Juji T.;
RT   "Polymorphism of TAPASIN and its linkage disequilibria with HLA class II
RT   genes in the Japanese population.";
RL   Tissue Antigens 52:279-281(1998).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT ARG-260.
RC   TISSUE=Neutrophil;
RX   PubMed=10088603; DOI=10.1002/jlb.65.2.205;
RA   El Ouakfaoui S., Heitz D., Paquin R., Beaulieu A.D.;
RT   "Granulocyte-macrophage colony-stimulating factor modulates tapasin
RT   expression in human neutrophils.";
RL   J. Leukoc. Biol. 65:205-210(1999).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND VARIANT ARG-260.
RC   TISSUE=B-cell;
RX   PubMed=14668790; DOI=10.1038/sj.gene.6364043;
RA   Gao B., Williams A., Sewell A., Elliott T.;
RT   "Generation of a functional, soluble tapasin protein from an alternatively
RT   spliced mRNA.";
RL   Genes Immun. 5:101-108(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4), ALTERNATIVE SPLICING, AND VARIANT
RP   ARG-260.
RC   TISSUE=Melanoma;
RX   PubMed=20600451; DOI=10.1016/j.humimm.2010.05.019;
RA   Belicha-Villanueva A., Golding M., McEvoy S., Sarvaiya N., Cresswell P.,
RA   Gollnick S.O., Bangia N.;
RT   "Identification of an alternate splice form of tapasin in human melanoma.";
RL   Hum. Immunol. 71:1018-1026(2010).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT ARG-260.
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R.,
RA   Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D.,
RA   Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H.,
RA   Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E.,
RA   Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J.,
RA   French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J.,
RA   Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C.,
RA   Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A.,
RA   Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R.,
RA   Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M.,
RA   Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K.,
RA   Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R.,
RA   Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A.,
RA   Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L.,
RA   Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y.,
RA   Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E.,
RA   Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A.,
RA   Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W.,
RA   Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M.,
RA   West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J.,
RA   Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M.,
RA   Bentley D.R., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Dunham I.,
RA   Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT ARG-260.
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3), AND VARIANT ARG-260.
RC   TISSUE=Prostate;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [12]
RP   MUTAGENESIS, AND DOMAIN CHARACTERIZATION.
RX   PubMed=10382748;
RX   DOI=10.1002/(sici)1521-4141(199906)29:06<1858::aid-immu1858>3.0.co;2-c;
RA   Bangia N., Lehner P.J., Hughes E.A., Surman M., Cresswell P.;
RT   "The N-terminal region of tapasin is required to stabilize the MHC class I
RT   loading complex.";
RL   Eur. J. Immunol. 29:1858-1870(1999).
RN   [13]
RP   FUNCTION.
RX   PubMed=10636848; DOI=10.1074/jbc.275.3.1581;
RA   Li S., Paulsson K.M., Chen S., Sjoegren H.-O., Wang P.;
RT   "Tapasin is required for efficient peptide binding to transporter
RT   associated with antigen processing.";
RL   J. Biol. Chem. 275:1581-1586(2000).
RN   [14]
RP   FUNCTION.
RX   PubMed=12582157; DOI=10.1074/jbc.m212882200;
RA   Park B., Ahn K.;
RT   "An essential function of tapasin in quality control of HLA-G molecules.";
RL   J. Biol. Chem. 278:14337-14345(2003).
RN   [15]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-253.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of multiple
RT   enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [17]
RP   FUNCTION, INTERACTION WITH HLA-A*02-B2M, AND MUTAGENESIS OF CYS-115 AND
RP   ASN-253.
RX   PubMed=21263072; DOI=10.4049/jimmunol.1002959;
RA   Rizvi S.M., Del Cid N., Lybarger L., Raghavan M.;
RT   "Distinct functions for the glycans of tapasin and heavy chains in the
RT   assembly of MHC class I molecules.";
RL   J. Immunol. 186:2309-2320(2011).
RN   [18]
RP   INTERACTION WITH TAP1-TAP2.
RX   PubMed=22638925; DOI=10.1007/s00018-012-1005-6;
RA   Hulpke S., Tomioka M., Kremmer E., Ueda K., Abele R., Tampe R.;
RT   "Direct evidence that the N-terminal extensions of the TAP complex act as
RT   autonomous interaction scaffolds for the assembly of the MHC I peptide-
RT   loading complex.";
RL   Cell. Mol. Life Sci. 69:3317-3327(2012).
RN   [19]
RP   CLEAVAGE OF SIGNAL PEPTIDE [LARGE SCALE ANALYSIS] AFTER ALA-20, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [20]
RP   FUNCTION, SUBUNIT, INTERACTION WITH TAP1-TAP2, SITE, AND MUTAGENESIS OF
RP   LYS-428.
RX   PubMed=26611325; DOI=10.1038/srep17341;
RA   Blees A., Reichel K., Trowitzsch S., Fisette O., Bock C., Abele R.,
RA   Hummer G., Schaefer L.V., Tampe R.;
RT   "Assembly of the MHC I peptide-loading complex determined by a conserved
RT   ionic lock-switch.";
RL   Sci. Rep. 5:17341-17341(2015).
RN   [21]
RP   INTERACTION WITH MR1, AND MUTAGENESIS OF GLU-205; ARG-207; GLN-209; LEU-270
RP   AND GLN-281.
RX   PubMed=32958637; DOI=10.1073/pnas.2011260117;
RA   McWilliam H.E.G., Mak J.Y.W., Awad W., Zorkau M., Cruz-Gomez S., Lim H.J.,
RA   Yan Y., Wormald S., Dagley L.F., Eckle S.B.G., Corbett A.J., Liu H., Li S.,
RA   Reddiex S.J.J., Mintern J.D., Liu L., McCluskey J., Rossjohn J.,
RA   Fairlie D.P., Villadangos J.A.;
RT   "Endoplasmic reticulum chaperones stabilize ligand-receptive MR1 molecules
RT   for efficient presentation of metabolite antigens.";
RL   Proc. Natl. Acad. Sci. U.S.A. 117:24974-24985(2020).
RN   [22]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 1-401 IN COMPLEX WITH PDIA3,
RP   SUBUNIT, INTERACTION WITH PDIA3, GLYCOSYLATION AT ASN-253, AND DISULFIDE
RP   BONDS.
RX   PubMed=19119025; DOI=10.1016/j.immuni.2008.10.018;
RA   Dong G., Wearsch P.A., Peaper D.R., Cresswell P., Reinisch K.M.;
RT   "Insights into MHC class I peptide loading from the structure of the
RT   tapasin-ERp57 thiol oxidoreductase heterodimer.";
RL   Immunity 30:21-32(2009).
RN   [23]
RP   INVOLVEMENT IN MHC1D3.
RX   PubMed=12149238; DOI=10.1182/blood-2001-12-0252;
RA   Yabe T., Kawamura S., Sato M., Kashiwase K., Tanaka H., Ishikawa Y.,
RA   Asao Y., Oyama J., Tsuruta K., Tokunaga K., Tadokoro K., Juji T.;
RT   "A subject with a novel type I bare lymphocyte syndrome has tapasin
RT   deficiency due to deletion of 4 exons by Alu-mediated recombination.";
RL   Blood 100:1496-1498(2002).
CC   -!- FUNCTION: Involved in the association of MHC class I with transporter
CC       associated with antigen processing (TAP) and in the assembly of MHC
CC       class I with peptide (peptide loading). {ECO:0000269|PubMed:10636848,
CC       ECO:0000269|PubMed:12582157, ECO:0000269|PubMed:21263072,
CC       ECO:0000269|PubMed:26611325}.
CC   -!- SUBUNIT: Heterodimer with PDIA3; disulfide-linked. Obligatory mediator
CC       for the interaction between newly assembled MHC class I molecules,
CC       calreticulin, PDIA3 and TAP. Up to 4 MHC class I/tapasin complexes bind
CC       to 1 TAP (PubMed:19119025, PubMed:21263072, PubMed:26611325). Interacts
CC       with HLA-G-B2M complex; this interaction is required for loading of
CC       high affinity peptides (PubMed:21263072). On its own or as part of MHC
CC       class I peptide loading complex, interacts with ligand-free MR1 or MR1-
CC       B2M complex, providing for stable MR1 pools ready for metabolite
CC       antigen processing (PubMed:32958637). {ECO:0000269|PubMed:12582157,
CC       ECO:0000269|PubMed:19119025, ECO:0000269|PubMed:21263072,
CC       ECO:0000269|PubMed:32958637}.
CC   -!- INTERACTION:
CC       O15533; P01892: HLA-A; NbExp=10; IntAct=EBI-874801, EBI-2839473;
CC       O15533; Q03518: TAP1; NbExp=13; IntAct=EBI-874801, EBI-747259;
CC       O15533; Q03519: TAP2; NbExp=8; IntAct=EBI-874801, EBI-780781;
CC       O15533; P0C739: BNLF2a; Xeno; NbExp=6; IntAct=EBI-874801, EBI-9346744;
CC       O15533; Q77CE4: gN; Xeno; NbExp=2; IntAct=EBI-874801, EBI-11303846;
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane {ECO:0000305};
CC       Single-pass type I membrane protein {ECO:0000305}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=O15533-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O15533-2; Sequence=VSP_002577;
CC       Name=3;
CC         IsoId=O15533-3; Sequence=VSP_017055;
CC       Name=4; Synonyms=tpsnDeltaEx3;
CC         IsoId=O15533-4; Sequence=VSP_044455;
CC   -!- TISSUE SPECIFICITY: Neutrophils, mostly in fully differentiated cells.
CC   -!- DOMAIN: The N-terminus is required for efficient association with MHC
CC       class I molecule and for a stable interaction between MHC I and
CC       calreticulin. Binding to TAP is mediated by the C-terminal region.
CC       {ECO:0000269|PubMed:10382748}.
CC   -!- POLYMORPHISM: The 2 alleles of TAPBP; TAPBP*01 (Tapasin*01) (shown
CC       here) and TAPBP*02 (Tapasin*02); are in linkage disequilibria with the
CC       HLA-DRB1 locus in a Japanese population. {ECO:0000269|PubMed:9802609}.
CC   -!- DISEASE: MHC class I deficiency 3 (MHC1D3) [MIM:620814]: An autosomal
CC       recessive disorder characterized by glomerulonephritis and markedly
CC       reduced cell surface expression of class I HLA antigens. Additional
CC       features are herpes zoster infection and polyps of the stomach and
CC       colon. {ECO:0000269|PubMed:12149238}. Note=The disease is caused by
CC       variants affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: [Isoform 2]: Due to a partial intron retention.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAD32924.2; Type=Miscellaneous discrepancy; Note=Probable cloning artifact.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=TAPBPbase; Note=TAPBP mutation db;
CC       URL="https://databases.lovd.nl/shared/genes/TAPBP";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; Y13582; CAA73909.1; -; mRNA.
DR   EMBL; AF009510; AAC20076.1; -; mRNA.
DR   EMBL; AB010639; BAA28757.1; -; mRNA.
DR   EMBL; AB012622; BAA28758.1; -; Genomic_DNA.
DR   EMBL; AB012920; BAA28759.1; -; Genomic_DNA.
DR   EMBL; AF029750; AAB82949.1; -; mRNA.
DR   EMBL; AF067286; AAD32924.2; ALT_SEQ; mRNA.
DR   EMBL; AF314222; AAG33061.1; -; mRNA.
DR   EMBL; EU693375; ACD68200.1; -; mRNA.
DR   EMBL; AL662820; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL662827; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BX248088; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CR759786; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CR759817; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; Z97183; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; Z97184; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471081; EAX03717.1; -; Genomic_DNA.
DR   EMBL; BC080574; AAH80574.1; -; mRNA.
DR   CCDS; CCDS34426.1; -. [O15533-1]
DR   CCDS; CCDS34427.2; -. [O15533-4]
DR   CCDS; CCDS34428.2; -. [O15533-3]
DR   RefSeq; NP_003181.3; NM_003190.4. [O15533-1]
DR   RefSeq; NP_757345.2; NM_172208.3. [O15533-3]
DR   RefSeq; NP_757346.2; NM_172209.3. [O15533-4]
DR   PDB; 3F8U; X-ray; 2.60 A; B/D=1-401.
DR   PDB; 6ENY; EM; 5.80 A; C=21-448.
DR   PDB; 7QNG; X-ray; 2.70 A; A=1-401.
DR   PDB; 7QPD; EM; 3.73 A; T=21-448.
DR   PDB; 7TUE; X-ray; 3.10 A; D=21-401.
DR   PDB; 7TUF; X-ray; 2.80 A; C/D=21-401.
DR   PDB; 7TUG; X-ray; 3.90 A; D=21-401.
DR   PDBsum; 3F8U; -.
DR   PDBsum; 6ENY; -.
DR   PDBsum; 7QNG; -.
DR   PDBsum; 7QPD; -.
DR   PDBsum; 7TUE; -.
DR   PDBsum; 7TUF; -.
DR   PDBsum; 7TUG; -.
DR   AlphaFoldDB; O15533; -.
DR   EMDB; EMD-14119; -.
DR   EMDB; EMD-3906; -.
DR   SMR; O15533; -.
DR   BioGRID; 112755; 122.
DR   ComplexPortal; CPX-2375; Tapasin-ERp57 complex.
DR   FunCoup; O15533; 494.
DR   IntAct; O15533; 68.
DR   MINT; O15533; -.
DR   STRING; 9606.ENSP00000404833; -.
DR   TCDB; 8.A.196.1.1; the tapasin (tapasin) family.
DR   TCDB; 9.A.75.1.2; the mhc ii receptor (mhc2r) family.
DR   GlyConnect; 1784; 2 N-Linked glycans (1 site).
DR   GlyCosmos; O15533; 1 site, 1 glycan.
DR   GlyGen; O15533; 3 sites, 2 N-linked glycans (1 site), 2 O-linked glycans (2 sites).
DR   iPTMnet; O15533; -.
DR   PhosphoSitePlus; O15533; -.
DR   SwissPalm; O15533; -.
DR   BioMuta; TAPBP; -.
DR   jPOST; O15533; -.
DR   MassIVE; O15533; -.
DR   PaxDb; 9606-ENSP00000404833; -.
DR   PeptideAtlas; O15533; -.
DR   ProteomicsDB; 20346; -.
DR   ProteomicsDB; 48740; -. [O15533-1]
DR   ProteomicsDB; 48741; -. [O15533-2]
DR   ProteomicsDB; 48742; -. [O15533-3]
DR   Pumba; O15533; -.
DR   TopDownProteomics; O15533-3; -. [O15533-3]
DR   Antibodypedia; 45647; 206 antibodies from 30 providers.
DR   CPTC; O15533; 2 antibodies.
DR   DNASU; 6892; -.
DR   Ensembl; ENST00000374572.7; ENSP00000363700.3; ENSG00000112493.12.
DR   Ensembl; ENST00000383065.8; ENSP00000372542.4; ENSG00000206208.11. [O15533-3]
DR   Ensembl; ENST00000383066.8; ENSP00000372543.4; ENSG00000206208.11. [O15533-1]
DR   Ensembl; ENST00000383197.8; ENSP00000372684.4; ENSG00000206281.11.
DR   Ensembl; ENST00000383198.6; ENSP00000372685.2; ENSG00000206281.11.
DR   Ensembl; ENST00000395114.7; ENSP00000378546.3; ENSG00000112493.12.
DR   Ensembl; ENST00000417059.5; ENSP00000402087.1; ENSG00000236490.9.
DR   Ensembl; ENST00000426633.6; ENSP00000404833.2; ENSG00000231925.15. [O15533-3]
DR   Ensembl; ENST00000434618.7; ENSP00000395701.2; ENSG00000231925.15. [O15533-1]
DR   Ensembl; ENST00000456807.6; ENSP00000407195.2; ENSG00000236490.9.
DR   Ensembl; ENST00000489157.6; ENSP00000419659.1; ENSG00000231925.15. [O15533-4]
DR   Ensembl; ENST00000551943.3; ENSP00000447665.1; ENSG00000206208.11. [O15533-4]
DR   Ensembl; ENST00000699659.1; ENSP00000514507.1; ENSG00000231925.15. [O15533-3]
DR   GeneID; 6892; -.
DR   KEGG; hsa:6892; -.
DR   MANE-Select; ENST00000434618.7; ENSP00000395701.2; NM_003190.5; NP_003181.3.
DR   UCSC; uc003odx.3; human. [O15533-1]
DR   AGR; HGNC:11566; -.
DR   ClinPGx; PA36331; -.
DR   CTD; 6892; -.
DR   DisGeNET; 6892; -.
DR   GeneCards; TAPBP; -.
DR   HGNC; HGNC:11566; TAPBP.
DR   HPA; ENSG00000231925; Low tissue specificity.
DR   MalaCards; TAPBP; -.
DR   MIM; 601962; gene.
DR   MIM; 620814; phenotype.
DR   OpenTargets; ENSG00000231925; -.
DR   Orphanet; 34592; Immunodeficiency by defective expression of MHC class I.
DR   VEuPathDB; HostDB:ENSG00000231925; -.
DR   eggNOG; ENOG502QR0A; Eukaryota.
DR   GeneTree; ENSGT00940000159200; -.
DR   InParanoid; O15533; -.
DR   OMA; YMPPTLE; -.
DR   OrthoDB; 8929156at2759; -.
DR   PAN-GO; O15533; 5 GO annotations based on evolutionary models.
DR   PhylomeDB; O15533; -.
DR   PathwayCommons; O15533; -.
DR   Reactome; R-HSA-1236974; ER-Phagosome pathway.
DR   Reactome; R-HSA-983170; Antigen Presentation: Folding, assembly and peptide loading of class I MHC.
DR   SignaLink; O15533; -.
DR   Agora; ENSG00000231925; -.
DR   BioGRID-ORCS; 6892; 17 hits in 1155 CRISPR screens.
DR   ChiTaRS; TAPBP; human.
DR   EvolutionaryTrace; O15533; -.
DR   GeneWiki; Tapasin; -.
DR   GenomeRNAi; 6892; -.
DR   Pharos; O15533; Tbio.
DR   PRO; PR:O15533; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   RNAct; O15533; protein.
DR   Bgee; ENSG00000231925; Expressed in bone marrow cell and 96 other cell types or tissues.
DR   ExpressionAtlas; O15533; baseline and differential.
DR   GO; GO:0005783; C:endoplasmic reticulum; IC:UniProt.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IDA:UniProtKB.
DR   GO; GO:0033116; C:endoplasmic reticulum-Golgi intermediate compartment membrane; TAS:Reactome.
DR   GO; GO:0000139; C:Golgi membrane; IDA:UniProtKB.
DR   GO; GO:0098553; C:lumenal side of endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0042824; C:MHC class I peptide loading complex; IDA:UniProtKB.
DR   GO; GO:0030670; C:phagocytic vesicle membrane; TAS:Reactome.
DR   GO; GO:0061779; C:Tapasin-ERp57 complex; IPI:ComplexPortal.
DR   GO; GO:0042288; F:MHC class I protein binding; TAS:UniProtKB.
DR   GO; GO:0023024; F:MHC class I protein complex binding; IBA:GO_Central.
DR   GO; GO:0060090; F:molecular adaptor activity; IDA:UniProt.
DR   GO; GO:0042605; F:peptide antigen binding; TAS:UniProtKB.
DR   GO; GO:0044183; F:protein folding chaperone; IDA:UniProt.
DR   GO; GO:0062061; F:TAP complex binding; IDA:UniProtKB.
DR   GO; GO:0046978; F:TAP1 binding; IDA:UniProtKB.
DR   GO; GO:0046979; F:TAP2 binding; IDA:UniProtKB.
DR   GO; GO:0051082; F:unfolded protein binding; TAS:UniProtKB.
DR   GO; GO:0019885; P:antigen processing and presentation of endogenous peptide antigen via MHC class I; IEA:InterPro.
DR   GO; GO:0002479; P:antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent; IEA:Ensembl.
DR   GO; GO:0002398; P:MHC class Ib protein complex assembly; IMP:UniProtKB.
DR   GO; GO:0002502; P:peptide antigen assembly with MHC class I protein complex; IDA:UniProt.
DR   GO; GO:0050823; P:peptide antigen stabilization; ISS:UniProtKB.
DR   GO; GO:0065003; P:protein-containing complex assembly; IDA:UniProtKB.
DR   GO; GO:0010468; P:regulation of gene expression; IMP:AgBase.
DR   GO; GO:0061635; P:regulation of protein complex stability; IDA:AgBase.
DR   GO; GO:0006890; P:retrograde vesicle-mediated transport, Golgi to endoplasmic reticulum; NAS:UniProtKB.
DR   FunFam; 2.60.40.10:FF:000924; TAP binding protein; 1.
DR   FunFam; 2.60.40.10:FF:001043; TAP binding protein; 1.
DR   FunFam; 2.60.40.10:FF:001044; TAP binding protein; 1.
DR   Gene3D; 2.60.40.10; Immunoglobulins; 3.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR036179; Ig-like_dom_sf.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR003597; Ig_C1-set.
DR   InterPro; IPR050380; Immune_Resp_Modulators.
DR   InterPro; IPR008056; Tapasin.
DR   PANTHER; PTHR23411; TAPASIN; 1.
DR   Pfam; PF07654; C1-set; 1.
DR   PRINTS; PR01669; TAPASIN.
DR   SUPFAM; SSF48726; Immunoglobulin; 1.
DR   PROSITE; PS50835; IG_LIKE; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Direct protein sequencing;
KW   Disulfide bond; Endoplasmic reticulum; Glycoprotein; Immunoglobulin domain;
KW   Membrane; Proteomics identification; Reference proteome; Signal;
KW   Transmembrane; Transmembrane helix.
FT   SIGNAL          1..20
FT                   /evidence="ECO:0007744|PubMed:25944712"
FT   CHAIN           21..448
FT                   /note="Tapasin"
FT                   /id="PRO_0000014990"
FT   TOPO_DOM        21..414
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        415..435
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        436..448
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          292..399
FT                   /note="Ig-like C1-type"
FT   SITE            428
FT                   /note="Inter-subunit salt bridge with TAP1-TAP2. Essential
FT                   peptide loading complex assembly"
FT                   /evidence="ECO:0000269|PubMed:26611325"
FT   SITE            428
FT                   /note="May be involved in interaction with TAP"
FT   CARBOHYD        253
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:19119025,
FT                   ECO:0000269|PubMed:19159218"
FT   DISULFID        27..91
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114,
FT                   ECO:0000269|PubMed:19119025"
FT   DISULFID        115
FT                   /note="Interchain (with C-57 in PDIA3)"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114,
FT                   ECO:0000269|PubMed:19119025"
FT   DISULFID        315..382
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114,
FT                   ECO:0000269|PubMed:19119025"
FT   VAR_SEQ         70..156
FT                   /note="Missing (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:20600451"
FT                   /id="VSP_044455"
FT   VAR_SEQ         405..448
FT                   /note="LSGPSLEDSVGLFLSAFLLLGLFKALGWAAVYLSTCKDSKKKAE -> KSWE
FT                   LCGI (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14668790"
FT                   /id="VSP_002577"
FT   VAR_SEQ         446..448
FT                   /note="KAE -> VQCSTSLYLSLVTLSPHPISKPMEGGCWCGRQNLGLEFTLIWVKT
FT                   WHYILTVGLFEHAT (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_017055"
FT   VARIANT         260
FT                   /note="T -> R (in allele TAPBP*01; dbSNP:rs2071888)"
FT                   /evidence="ECO:0000269|PubMed:10088603,
FT                   ECO:0000269|PubMed:14574404, ECO:0000269|PubMed:14668790,
FT                   ECO:0000269|PubMed:15489334, ECO:0000269|PubMed:20600451,
FT                   ECO:0000269|PubMed:9238042, ECO:0000269|PubMed:9271576,
FT                   ECO:0000269|PubMed:9521053, ECO:0000269|PubMed:9802609,
FT                   ECO:0000269|Ref.10"
FT                   /id="VAR_010253"
FT   MUTAGEN         115
FT                   /note="C->A: Abolishes the recruitment of PDIA3, CALR and
FT                   B2M to the peptide-loading complex."
FT                   /evidence="ECO:0000269|PubMed:21263072"
FT   MUTAGEN         205
FT                   /note="E->K: Decreases cell surface expression of
FT                   MR1-metabolite antigen complex; when associated with E-207,
FT                   S-209 and S-281."
FT                   /evidence="ECO:0000269|PubMed:32958637"
FT   MUTAGEN         207
FT                   /note="R->E: Decreases cell surface expression of
FT                   MR1-metabolite antigen complex; when associated with E-205,
FT                   S-209 and S-281."
FT                   /evidence="ECO:0000269|PubMed:32958637"
FT   MUTAGEN         209
FT                   /note="Q->S: Decreases cell surface expression of
FT                   MR1-metabolite antigen complex; when associated with E-205,
FT                   S-207 and S-281."
FT                   /evidence="ECO:0000269|PubMed:32958637"
FT   MUTAGEN         253
FT                   /note="N->Q: Reduces the recruitment of PDIA3 to TAP1-TAP2
FT                   transporter."
FT                   /evidence="ECO:0000269|PubMed:21263072"
FT   MUTAGEN         270
FT                   /note="L->K: Decreases cell surface expression of
FT                   MR1-metabolite antigen complex."
FT                   /evidence="ECO:0000269|PubMed:32958637"
FT   MUTAGEN         281
FT                   /note="Q->S: Decreases cell surface expression of
FT                   MR1-metabolite antigen complex; when associated with E-205,
FT                   S-207 and S-209."
FT                   /evidence="ECO:0000269|PubMed:32958637"
FT   MUTAGEN         428
FT                   /note="K->D: Restores interaction with TAP1-TAP2; when
FT                   associated with TAP1 K-92 or TAP2 K-16."
FT                   /evidence="ECO:0000269|PubMed:26611325"
FT   CONFLICT        274
FT                   /note="H -> Y (in Ref. 11; AAH80574)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        296
FT                   /note="L -> P (in Ref. 8; ACD68200)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        412
FT                   /note="D -> N (in Ref. 7; AAD32924)"
FT                   /evidence="ECO:0000305"
FT   STRAND          23..29
FT                   /evidence="ECO:0007829|PDB:3F8U"
FT   TURN            34..36
FT                   /evidence="ECO:0007829|PDB:7QNG"
FT   STRAND          41..46
FT                   /evidence="ECO:0007829|PDB:3F8U"
FT   STRAND          50..52
FT                   /evidence="ECO:0007829|PDB:7QNG"
FT   STRAND          58..60
FT                   /evidence="ECO:0007829|PDB:7TUF"
FT   HELIX           62..64
FT                   /evidence="ECO:0007829|PDB:7QNG"
FT   STRAND          65..69
FT                   /evidence="ECO:0007829|PDB:3F8U"
FT   HELIX           74..81
FT                   /evidence="ECO:0007829|PDB:3F8U"
FT   STRAND          90..96
FT                   /evidence="ECO:0007829|PDB:3F8U"
FT   HELIX           104..109
FT                   /evidence="ECO:0007829|PDB:3F8U"
FT   STRAND          112..116
FT                   /evidence="ECO:0007829|PDB:3F8U"
FT   HELIX           117..119
FT                   /evidence="ECO:0007829|PDB:3F8U"
FT   STRAND          123..129
FT                   /evidence="ECO:0007829|PDB:3F8U"
FT   STRAND          134..141
FT                   /evidence="ECO:0007829|PDB:3F8U"
FT   STRAND          148..150
FT                   /evidence="ECO:0007829|PDB:3F8U"
FT   STRAND          153..164
FT                   /evidence="ECO:0007829|PDB:3F8U"
FT   STRAND          169..171
FT                   /evidence="ECO:0007829|PDB:3F8U"
FT   STRAND          176..178
FT                   /evidence="ECO:0007829|PDB:3F8U"
FT   STRAND          181..184
FT                   /evidence="ECO:0007829|PDB:3F8U"
FT   HELIX           188..191
FT                   /evidence="ECO:0007829|PDB:7TUF"
FT   STRAND          203..210
FT                   /evidence="ECO:0007829|PDB:3F8U"
FT   STRAND          213..220
FT                   /evidence="ECO:0007829|PDB:3F8U"
FT   STRAND          236..242
FT                   /evidence="ECO:0007829|PDB:3F8U"
FT   STRAND          246..248
FT                   /evidence="ECO:0007829|PDB:7TUF"
FT   STRAND          250..258
FT                   /evidence="ECO:0007829|PDB:3F8U"
FT   HELIX           263..265
FT                   /evidence="ECO:0007829|PDB:3F8U"
FT   STRAND          267..275
FT                   /evidence="ECO:0007829|PDB:3F8U"
FT   STRAND          278..290
FT                   /evidence="ECO:0007829|PDB:3F8U"
FT   STRAND          293..300
FT                   /evidence="ECO:0007829|PDB:3F8U"
FT   STRAND          302..304
FT                   /evidence="ECO:0007829|PDB:7TUF"
FT   TURN            306..308
FT                   /evidence="ECO:0007829|PDB:7TUF"
FT   STRAND          313..323
FT                   /evidence="ECO:0007829|PDB:3F8U"
FT   STRAND          327..337
FT                   /evidence="ECO:0007829|PDB:3F8U"
FT   STRAND          345..349
FT                   /evidence="ECO:0007829|PDB:3F8U"
FT   STRAND          360..367
FT                   /evidence="ECO:0007829|PDB:3F8U"
FT   HELIX           373..375
FT                   /evidence="ECO:0007829|PDB:3F8U"
FT   STRAND          379..385
FT                   /evidence="ECO:0007829|PDB:3F8U"
FT   STRAND          394..399
FT                   /evidence="ECO:0007829|PDB:3F8U"
SQ   SEQUENCE   448 AA;  47571 MW;  9F7BF490BA148B08 CRC64;
     MKSLSLLLAV ALGLATAVSA GPAVIECWFV EDASGKGLAK RPGALLLRQG PGEPPPRPDL
     DPELYLSVHD PAGALQAAFR RYPRGAPAPH CEMSRFVPLP ASAKWASGLT PAQNCPRALD
     GAWLMVSISS PVLSLSSLLR PQPEPQQEPV LITMATVVLT VLTHTPAPRV RLGQDALLDL
     SFAYMPPTSE AASSLAPGPP PFGLEWRRQH LGKGHLLLAA TPGLNGQMPA AQEGAVAFAA
     WDDDEPWGPW TGNGTFWLPT VQPFQEGTYL ATIHLPYLQG QVTLELAVYK PPKVSLMPAT
     LARAAPGEAP PELLCLVSHF YPSGGLEVEW ELRGGPGGRS QKAEGQRWLS ALRHHSDGSV
     SLSGHLQPPP VTTEQHGARY ACRIHHPSLP ASGRSAEVTL EVAGLSGPSL EDSVGLFLSA
     FLLLGLFKAL GWAAVYLSTC KDSKKKAE
//
